Editas Medicine (EDIT) Capital Expenditures (2015 - 2025)

Editas Medicine (EDIT) has reported Capital Expenditures for 11 consecutive years, with -$1000.0 the latest figure, recorded in Q3 2025.

• In Q3 2025, Capital Expenditures fell 100.03% year-over-year to -$1000.0; the TTM figure through Sep 2025 stood at -$486000.0 (down 105.07% YoY), while the FY2024 annual figure was $8.8 million, up 87.03% from the prior year.
• Capital Expenditures rose to -$1000.0 in Q3 2025 per EDIT's latest filing, from -$1.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.5 million in Q2 2024 and bottomed at -$1.0 million in Q1 2025.
• Historically, Capital Expenditures has averaged $1.4 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2024 — Capital Expenditures surged 1122.18% — and 2025, when it slumped 154.78%.
• Editas Medicine's Capital Expenditures stood at $2.8 million in 2021, then slumped by 78.07% to $624000.0 in 2022, then soared by 109.46% to $1.3 million in 2023, then tumbled by 58.68% to $540000.0 in 2024, then slumped by 100.19% to -$1000.0 in 2025.
• Business Quant data shows EDIT's Capital Expenditures at -$1000.0 in Q3 2025, -$1.0 million in Q1 2025, and $540000.0 in Q4 2024.